The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $93.71

Today's change-4.80 -4.87%
Updated February 8 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $93.71

Today's change-4.80 -4.87%
Updated February 8 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc down (U.S.)$4.80

Intercept Pharmaceuticals Inc closed sharply lower Monday, dropping (U.S.)$4.80 or 4.87% to (U.S.)$93.71. Over the last five days, shares have lost 10.98% and sit 4.12% above their 52-week low. This security has underperformed the S&P 500 by 41.75% during the last year.

Key company metrics

  • Open(U.S.) $96.68
  • Previous close(U.S.) $98.51
  • High(U.S.) $97.70
  • Low(U.S.) $92.33
  • Bid / Ask(U.S.) $93.13 / (U.S.) $94.56
  • YTD % change-37.25%
  • Volume1,194,716
  • Average volume (10-day)877,084
  • Average volume (1-month)604,953
  • Average volume (3-month)562,351
  • 52-week range(U.S.) $90.00 to (U.S.) $314.88
  • Beta-2.43
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$7.50
Updated February 8 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-6,221.19%

Intercept Pharmaceuticals Inc has a net profit margin of -6,221.19%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX1.79%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue0010
Total other revenue--------
Total revenue0010
Gross profit--------
Total cost of revenue--------
Total operating expense52494136
Selling / general / administrative25211312
Research & development27282824
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-52-49-40-35
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-51-48-39-35
Income after tax-51-48-39-35
Income tax, total--------
Net income-51-48-39-35
Total adjustments to net income--------
Net income before extra. items-51-48-39-35
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-51-48-39-35
Inc. avail. to common incl. extra. items-51-48-39-35
Diluted net income-51-48-39-35
Dilution adjustment--------
Diluted weighted average shares24242221
Diluted EPS excluding extraordinary itemsvalue per share-2.10-1.99-1.78-1.63
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-2.10-1.99-1.78-1.63